#1Investor Overview July 2023 zoetis#2Zoetis at a glance 70+ Years of Experience We provide: Medicines Vaccines Diagnostics Genetic tests Biodevices Precision animal health $8.1B Annual revenue 100+ Countries with market presence 1,430 Approximate R&D colleagues 7 Major product categories 29 Manufacturing sites 4,200 Approximate field force members Note: Facts and figures shown are as of Dec. 31, 2022 ¹Excludes revenue associated with Client Supply Services and Human Health, which represented 1% of total 2022 revenue. 8 Core animal species Revenue from 64% companion animal products ¹ Revenue from livestock products 1 35% 13,800 Approximate colleagues worldwide#3Our Executive Team 3 Kristin Peck Chief Executive Officer Nick Ashton Executive Vice President and President, Global Manufacturing and Supply Jeannette Ferran Astorga Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer Ester Banque Executive Vice President and President, U.S. Operations Wetteny Joseph Executive Vice President and Chief Financial Officer Jamie Brannan Executive Vice President and President, International Operations and Aquaculture Roxanne Lagano Executive Vice President, Chief Human Resources Officer and Global Operations Heidi Chen Executive Vice President, General Counsel & Corporate Secretary; Business Lead of Human Health Diagnostics Wafaa Mamilli Executive Vice President, Chief Digital and Technology Officer and Group President, China, Brazil and Precision Animal Health Rimma Driscoll Executive Vice President, Head of Global Strategy, Commercial and Business Development, and Global BioDevices Rob Polzer Executive Vice President and President, Research and Development zoetis#4Our Core Beliefs Our core beliefs form the foundation of our culture 4 Our colleagues make the difference Always do the right thing Customer obsessed Run it like you own it We are one Zoetis zoetis#5Our Purpose To nurture our world and humankind by advancing care for animals Our Vision To be the most trusted and valued animal health company, shaping the future of animal care through our innovation, customer obsession and purpose-driven colleagues 5 Our Strategic Priorities Lead Through Innovation Across Our Diverse Portfolio Deliver an Exceptional Experience to Delight Our Customers 1 4 Support a Workplace Where Our Colleagues Can Thrive 2 5 Advance Sustainability in Animal Health for a Better Future 3 6 Power Our Business Through Digital Solutions and Data Insights Perform with Excellence and Agility zoetis#6CONTINUUM OF CARE Innovating Across the Continuum of Care 6 predict Treat Detect Prevent PREDICT PREVENT DETECT TREAT Co Genetics Vaccines, robotics and automation Data analytics and sensors Diagnostics Medicines zoetis#7Diverse, Durable and Innovative Portfolio Diversity across geographies, species and therapeutic areas drives steady performance 7 7 therapeutic areas 15¹ blockbusters ~300 product lines 8 core species -30² year average market life of key brands in portfolio >2,000 new products and lifecycle innovations introduced in last 10 years ¹ Number of blockbuster products with revenues of $100M or more as of year-end 2022 2 Market life refers to the number of years a product has been commercially available. zoetis#8World Leader in Animal Health ¹ By Species Market Leader in Species Representing ~90% of Our Portfolio by Revenue ³ Companion Animal #1 Cattle 8 Fish ³ Swine Poultry #1 #1 #2 #5 By Product Category Other Pharma² Anti-Infectives Medicated Feed Additives (MFA) Vaccines (Biologicals) Diagnostics 3 Parasiticides 1 Vetnosis Executive's Guide April 2023. Rankings are based on revenues. 2 Includes pain, sedation, internal medicine, dermatology, etc. 3 Zoetis internal estimates #1 #1 #2 #3 #3 #2 By Geography North America Latin America Asia Eastern Europe Western Europe #1 #1 #1 #2 #2 High Growth Franchise Areas ³ Dermatology Pet Pain Pet Parasiticides #1 #1 #2 zoetis#9Five Key Growth Drivers in 2023 9 ez Companion animal parasiticides Osteoarthritis (OA) pain Key dermatology portfolio Global diagnostics Growth in emerging markets. zoetis#1010 86% of pet owners would pay whatever it takes if their pet needed extensive veterinary care.1 KEY TRENDS IN PETCARE The Human-Animal Bond Pet owners are prioritizing health and wellness of their animals Gen-Z and Millennials are fueling the humanization of pets High income households often have more than one pet and are more willing to spend during a down economy When faced with a 20% decrease in budget, pet owners will not spend less on their pets.² ¹ International Survey of Pet Owners and Veterinarians from HABRI/Zoetis. Published January 2022. 2 Zoetis Market Research, Dec. 2022 zoetis#11KEY TRENDS IN LIVESTOCK Healthy Animals Meeting Protein Demand The global population is growing, leading to increased demand for animal protein sources ● 11 Diverse portfolio across markets and therapeutic areas to serve wide range of species Nearly 2 billion more mouths to feed by 2050 (Global pop. of 9.7 billion in 2050¹) Limited resources and climate concerns are increasing need for sustainable production of meat, milk, fish and eggs Our ultimate goal is to enable animals to be healthy and productive 1 Based on estimates from the United Nations Zoetis#12High-Quality Products, Delivered by Our World-Class Manufacturing Operations Ę 12 Excellence in quality Breadth of expertise Reliable supply Speed to market Cost/efficiency improvements Carbon neutrality and renewable energy by 2030 Charles City, IA Eagle Grove, IA Lincoln, NE Union City, CA Buellton, CA San Diego, CA Chicago Heights, IL Kalamazoo, MI Willow Island, WV Salisbury, MD Durham, NC White Hall, IL Atlanta, GA Tallaght, Tullamore and Rathdrum, Ireland NOTE: Sites shown are as of May 10, 2023 Overhalla, Norway Klofta, Norway Farum, Denmark LLN, Belgium Olot, Spain Campinas, Brazil -Weibern, Austria Medolla, Italy Catania, Italy Suzhou, China Rutherford, Australia Melbourne, Australia Wellington, NZ zoetis#13Global Leadership, Scale and Scope Zoetis combines the local presence and knowledge necessary to serve the unique needs of individual customers with the global reach and resources essential to help advance animal health globally. 13 Revenue by market¹ 3% 4% 4% 5% 3% 6% 2% 2% 2% 9% 2% 2% 1% 1% United States 54% China 5% Brazil 4% Australia 4% Canada 3% United Kingdom 3% Germany 2% Japan 2% 54% Note: Based on 2022 revenue 1 Excludes revenue associated with Client Supply Services and Human Health, which represented 1% of total 2022 revenue Chile 2% Mexico 2% France 2% Spain 1% Italy 1% Other Emerging Markets 9% Other Developed Markets 6% zoetis#14Delivering Above-Market Operational Revenue Growth Operational revenue growth¹ vs. market² 4% 14 8% 2017 Market Revenue Growth 5% 8% 3 2018 Zoetis Revenue Growth 2% 8% 3 2019 6% 8% 3 2020 10% 15% 2021 3%² 8% 2022 1 Operational revenue growth (a non-GAAP financial measure) excludes the impact of foreign exchange. Reconciliations of non-GAAP financial measures are available in the appendix to this presentation. 2 Vetnosis "Review 2022" dated May 2023. Market estimate for 2022 based on Zoetis internal estimates. 3 Organic operational growth (a non-GAAP financial measure) excludes the impact of the acquisition of Abaxis in 2018 and 2019 and other acquisitions in 2020, as well as foreign exchange; if included, operational revenue growth was 10%, 10% and 9% in 2018, 2019 and 2020, respectively. zoetis#15Margin Expansion and Adjusted Net Income Growth Faster than Revenue Adjusted net income and adjusted EBIT margin¹ 15 Adjusted Net Income ($USD M) 34% $1,185 2017 35% $1,525 2018 Adjusted EBIT Margin 37% $1,755 2019 37% $1,844 2020 38% $2,240 2021 38% $2,297 2022 ¹Adjusted net income (a non-GAAP financial measure) is defined as reported U.S. generally accepted accounting principle (GAAP) net income excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted Earnings Before Interest and Taxes (EBIT) margin, a non-GAAP financial measure, excludes interest expense net of capitalized interest, interest income and adjusted income taxes (a non-GAAP measure). Reconciliations of non-GAAP financial measures are available in the appendix to this presentation. zoetis#16We remain committed to the four tenets of our Value Proposition DOOOO Grow revenue faster than the market 16 & Invest in innovation and growth capabilities Increase adjusted net income faster than revenue zoetis Return excess capital to shareholders#17Award- Winning Culture and Workplace 17 WORLD'S MOST ETHICAL COMPANIES® ETHISPHERE BEST HUMAN RIGHTS CAMPAIGN PLACES TO WORK EURUSTION TM 2022 for LGBTQ+ Equality 100% CORPORATE EQUALITY INDEX seramount part of EAB TOP COMPANY FOR EXECUTIVE WOMEN 2022 seramount BEST COMPANY FOR DADS part of EAS 2022 LATINO LEADERS 25 BEST COMPANIES FOR LATINOS TO WORK 2021 CHINA 2022 KINCENTRIC> Best Employer seramount 100 BEST COMPANY part of EAB 2022 Great Place To Work® Great Place To Work Certified JUN 2022-JUN 2023 DE Best Workplaces™ for Women ITALIA 2023 DiversityInc TOP COMPANIES FOR BOARD OF DIRECTORS 2022 Best Workplaces Great Place To Work. Best Workplaces™ for Inclusion Great Place TURKEY 2022 To Work CANADA 2021 zoetis